Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J Ends Hep C Drug Program

Janssen Sciences Ireland UC, a Johnson & Johnson company, announced the decision to halt development of its hepatitis C treatment combination JNJ-4178.

Read More »

Cancer immunotherapy proves itself in earlier-stage disease

Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors.

Read More »

AstraZeneca rebuilds cancer drug hopes with new lung data

Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July 2017’s big clinical trial setback in the disease.

Read More »

Death puts Cellectis cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Read More »

Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.’s Keytruda

Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.

Read More »

Five Prime Terminates $460 Million Immuno-oncology Deal With SoCal Biotech Inhibrx

Two years after forging a collaborative and licensing agreement with Southern California-based Inhibrx LLC, Five Prime Therapeutics Inc. walked away from the deal that includes an early cancer drug candidate.

Read More »

Storm Harvey could financially hurt already strained Houston hospitals

Structural improvements over the last decade to Houston hospitals have helped them to avoid devastation like Hurricane Katrina in New Orleans in 2005, but the pounding it received from Tropical Storm Harvey is expected to financially hobble many already strained Texas medical centers.

Read More »

CSL Behring Scoops U.S. Biotech Calimmune

CSL Ltd. bought Tucson, Ariz.-based Calimmune for $91 million upfront and up to $325 million in performance-based milestones.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom